Stay updated with breaking news from Chris Morabito. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Astria Therapeutics, Inc. , a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will share STAR-0215 Phase 1a...
Astria Therapeutics, Inc. , a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, is presenting new STAR-0215 data in a poster...
Astria Therapeutics, Inc. (ATXS) Friday announced new phase 1 a data confirming the potential for STAR-0125 to prevent Hereditary Angioedema or HAE attacks with dosing 2 or 4 times per year.
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, is presenting new STAR-0215 data in a poster presentation at the American College of Allergy, Asthma, and Immunology (ACAAI) in Anaheim,...
Operator: Good morning and welcome to the Astria Therapeutics 2022 Q4 and Full Year Financial Results and Business Update Conference Call. At this time, all attendees are in a listen-only mode.